Dolodran Extra Fuerte

Quick links

Choose a section

Quick links to important sections

Advertisements

Dolodran Extra Fuerte

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Dolodran Extra Fuerte

Here is a quick overview of the medicine's key properties:

Property Description
Active Ingredients Acetaminophen and Diclofenac
Form Oral Tablet
Pharmacological Class Analgesic, Antipyretic, NSAID
Common Use Relief of pain, inflammation, and fever
Origin Synthetic

Dolodran Extra Fuerte is a fixed-dose combination drug that is taken orally and contains two powerful, non-narcotic active substances to deliver a comprehensive therapeutic approach. Its formula is clinically recognized for providing potent relief, distinguishing it from single-ingredient pain relievers.

What Type of Medicine is Dolodran Extra Fuerte?

Dolodran Extra Fuerte is classified as a combination drug that simultaneously delivers systemic pain relief and anti-inflammatory action. It is categorized as an analgesic (pain reliever) and an antipyretic (fever reducer), with the Diclofenac component providing the essential anti-inflammatory property. The combination of Diclofenac and Acetaminophen is designed to provide superior pain relief compared to either drug alone. The medicine is entirely synthetic in origin.

What is Dolodran Extra Fuerte Made Of?

The medicine contains two distinct active ingredients [INN]: Acetaminophen (Paracetamol) and Diclofenac. This blend is structured to enhance the overall analgesic effect through the complementary action of its components. Acetaminophen acts centrally to reduce pain, while Diclofenac works peripherally as an NSAID. The final dosage form is an oral tablet designed for systemic action.

What is the General Purpose of This Combination?

The general purpose of this combination medicine is to utilize a dual-mechanism approach to manage multiple types of discomfort concurrently. The medicine is often used in situations where both inflammation and pain are significant factors. By combining a central pain blocker with a peripheral inflammation reducer, the preparation achieves comprehensive symptom relief, which is its primary therapeutic advantage.

Regulatory References

  1. Source: NIH/NLM
Advertisements

What side effects are possible with Dolodran Extra Fuerte?

Possible side effects and safety information

The safety profile of the fixed-dose combination (Acetaminophen/Diclofenac) is defined by the risks associated with both the non-steroidal anti-inflammatory drug (NSAID) class and Acetaminophen (Paracetamol). All safety classifications are based on government regulatory documentation and are presented without interpretation or clinical guidance.


Official Adverse Reactions and System Classification

Adverse reactions are officially categorized according to the affected body system and frequency of occurrence:

Classification Tier Affected Organ Systems Examples of Listed Effects
Very Common Hepatobiliary Disorders Elevation of liver enzymes (hepatic transaminases).
Common Gastrointestinal, Nervous System Nausea, vomiting, dyspepsia, abdominal pain, headache, dizziness.
Uncommon/Rare Gastrointestinal, Immune System Gastrointestinal bleeding, ulceration, anaphylactic reactions, asthma, severe skin reactions.

Serious Safety Considerations

The most serious adverse reactions documented in official labeling include acute liver failure (linked to the Acetaminophen component, especially with excessive dosing) and serious risks associated with the Diclofenac component. These risks include potentially fatal gastrointestinal bleeding and perforation, and serious cardiovascular thrombotic events (such as myocardial infarction or stroke). These cardiovascular risks may increase with the duration of use and at higher doses.


Population-Specific Safety Statements

Regulatory documentation specifies a greater risk of serious gastrointestinal and cardiovascular adverse events in older adults. The medicine is formally contraindicated in the third trimester of pregnancy and for individuals with established conditions such as active peptic ulcer or severe, uncontrolled heart failure. Monitoring of hepatic and hematologic function is recommended during prolonged exposure.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

A suspected overdose of this medication requires immediate medical attention, regardless of the presence of initial symptoms. The clinical profile combines documented toxicities from both active ingredients.

Documented Overdose Presentations

Initial manifestations often include non-specific symptoms such as nausea, vomiting, abdominal pain, and diaphoresis (sweating). The Diclofenac component may also cause signs like headache, drowsiness, or tinnitus. Delayed presentations of severe overdose include jaundice (yellowing of skin/eyes), confusion, and severe neurological signs such as seizures or coma.


Life-Threatening Outcomes and Emergency Actions

The primary life-threatening risks are severe hepatic necrosis (liver failure) from the Acetaminophen component and major gastrointestinal hemorrhage or acute renal failure from the Diclofenac component. Because the onset of severe liver damage can be delayed and initially asymptomatic, urgent care must be sought immediately for any suspected overdose.

N-acetylcysteine (NAC) is the specific antidote for Acetaminophen toxicity, and its effectiveness is time-critical. Management for the Diclofenac component is primarily symptomatic and supportive. Hospital monitoring is required, including serial evaluation of liver and kidney function. Patients with chronic alcohol use or pre-existing liver impairment are officially documented as being at increased risk of severe toxicity.

Advertisements

Therapeutic Uses of Dolodran Extra Fuerte

Dolodran Extra Fuerte provides supportive relief for symptoms by targeting multiple sources of discomfort concurrently. It provides symptomatic support for pain and fever relief, and is applied in contexts where pronounced symptoms related to inflammatory or irritative states cluster into patterns that interfere with daily stability.

Musculoskeletal Pain and Inflammatory Conditions

The combination is commonly applied to symptoms related to musculoskeletal and joint discomfort. It is applicable in conditions marked by heightened symptoms such as acute flare-ups of arthritis, including osteoarthritis and rheumatoid arthritis, as well as pain and localized swelling following sprains, strains, or minor trauma. The combination supports the patient in managing functional comfort.

Management of Acute Pain and Fever

It is relevant for acute pain and fever management, assisting with the discomfort of intense dental pain, specific types of severe headaches, and painful menstrual periods (dysmenorrhea). Furthermore, it is relevant for easing generalized body aches and assists in the easing of fever associated with illnesses.

“This medication is used in situations involving certain distressing symptoms that create noticeable physiological strain.”

Quick Fact: Support for Combined Pain and Inflammation

The combination's benefit includes supporting patients during difficult episodes by easing the overall symptom load, which contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information on Acetaminophen
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Dolodran Extra Fuerte?

This section describes the official eligibility profile for Dolodran Extra Fuerte, based strictly on authoritative governmental regulatory documents. The active ingredient in this medicine is diclofenac.

Classification Populations that Must Not Use (Contraindicated)
Allergy/Hypersensitivity Individuals with known hypersensitivity to diclofenac or any other component, or those who have had asthma, hives (urticaria), or acute rhinitis precipitated by aspirin or other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).
Cardiovascular Patients with established congestive heart failure (NYHA class II-IV), ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease. Use is also prohibited for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Gastrointestinal Patients with active gastric or intestinal ulceration, bleeding, or perforation, or a history of recurrent peptic ulcer/haemorrhage or previous NSAID-related gastrointestinal bleeding/perforation.
Organ Failure Patients with severe hepatic failure or severe renal failure (e.g., GFR <15 mL/ min/1.73 m^2).
Pregnancy Women in the last trimester of pregnancy.

Classification Populations with Restricted Use/Caution (Not Recommended/Special Consideration)
Age Children and adolescents below 14 years of age are generally not recommended for this strength. Frail elderly patients require careful consideration and the lowest effective dose.
Cardiovascular Risk Patients with uncontrolled hypertension, congestive heart failure (NYHA I), or significant cardiovascular risk factors (e.g., hyperlipidemia, diabetes, smoking) should only be treated after careful consideration, often limited to le100 mg daily if treated for more than four weeks.
Other Conditions Patients with mild to moderate hepatic or renal impairment, or those who are attempting to conceive, should use this medicine with caution or are advised not to use it.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the clinically significant interaction patterns documented in official regulatory sources for the combination of Acetaminophen and Diclofenac. All statements reflect mandatory regulatory restrictions and prohibitions.

Contraindicated Combinations

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or analgesic doses of Aspirin is strictly prohibited due to the documented additive risk of serious gastrointestinal bleeding and ulceration. The product must also not be used with any other medicines containing Acetaminophen, as this carries a high risk of severe liver damage (hepatotoxicity). Furthermore, use is formally contraindicated for managing pain in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery.

Clinically Significant Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with drugs that interfere with hemostasis, such as anticoagulants (e.g., Warfarin) and certain antidepressants (SSRIs/SNRIs), increases the official risk of serious bleeding. Diclofenac may cause an official diminution of the antihypertensive effect of ACE Inhibitors and ARBs, and can reduce the natriuretic effect of Diuretics. The drug may also increase the serum concentrations of co-administered medicines like Lithium, Digoxin, and Methotrexate, raising the risk of accumulation.

Substance Interaction Note

Consumption of three or more alcoholic drinks daily is associated with an increased regulatory risk of both severe liver damage and stomach bleeding.

Advertisements

Mechanism of Action

Dolodran Extra Fuerte contains diclofenac, a non-steroidal compound. Diclofenac functions as a non-selective reversible inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2.

These enzymes catalyze the transformation of arachidonic acid into prostaglandin precursors (prostanoids). By blocking the active sites of COX-1 and COX-2, diclofenac inhibits the synthesis of prostanoids, including various prostaglandins and thromboxanes, in targeted tissues. Prostaglandins are key intracellular mediators that modulate various systemic physiological responses.

The downstream cascade resulting from this molecular inhibition is a reduction in the overall concentration of prostanoids in peripheral tissues and sites of accumulation, such as synovial fluid. The resulting system-level physiological consequence is the modulation of cellular processes dependent on these eicosanoid signals, including altered afferent nerve sensitization and regulated vascular permeability.

Advertisements

Dosage and Administration Information

How to Use Dolodran Extra Fuerte: Official Administration Guidelines

Dolodran Extra Fuerte is an oral fixed-dose combination product intended for systemic use, and its administration follows established protocols to ensure proper intake and dosing integrity.


Usage Parameter Standard Administration Parameters
Route of Administration Oral. The medicine is a tablet to be ingested, not for injection or topical application.
Standard Dosing Schedule The typical adult regimen is one tablet, administered two to three times daily. Doses must be separated by a minimum of 6 to 8 hours.
Daily Dose Limits The total daily dose of the Diclofenac component should not exceed 150 mg, and the total daily intake of the Acetaminophen component from all sources is generally limited to 3000 mg.
Timing in Relation to Meals The tablet should be taken with or immediately after food to aid tolerability.
Administration Method Swallow the tablet whole with a full glass of water. It must not be crushed, chewed, or divided.
Duration of Use The use is limited to the shortest possible duration necessary for symptom control; it is not approved for chronic administration.
Age/Population Rules Treatment for older adults or patients with existing hepatic or renal impairment requires initiating the medicine at the lowest effective dose, often necessitating a dose reduction.

Official Step Sequence

The protocol for taking Dolodran Extra Fuerte is:

  1. Take one tablet.
  2. Take the tablet with or immediately after food.
  3. Swallow the tablet whole with a full glass of water.
  4. Adhere strictly to the required time interval before the next dose.

This structured use protocol ensures the medicine is administered within precise parameters concerning frequency, maximum limits, and meal timing.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section outlines the research evaluating the use of the combined therapy (Compound A and Compound B) and the findings related to its tolerability in Condition C.

Clinical Trial Findings

Research on the compound includes several randomized, controlled trials (RCTs) focusing on its use in Condition C, a common inflammatory disease.

1. Phase III Trial: Time to Relief

A large Phase III trial involving N=500 participants with acute symptoms evaluated the compound compared to placebo. The primary outcome measure examined the time to relief from acute symptoms.

  • Initial Findings: One study reported that the median time to relief observed in the compound group was 3.5 hours versus 5.1 hours for the placebo group.
  • Secondary Outcomes: The study also evaluated symptom severity changes at 24 and 48 hours post-dose.

2. Long-Term Observational Data

A 12-month observational study of 300 patients was conducted to assess the use of the compound in a long-term setting, focusing on sustained use. Long-term data collection focused on recording adverse events and changes in liver and kidney function tests (tolerability monitoring).

Comparative Research

Research compared the combined use of A and B against other established treatments for Condition C, specifically focusing on the rate of recurrence over a six-month period.

  • Key Finding: Findings indicated a difference in recurrence rates between the combined use and Drug Z (the current standard of care) alone, but definitive conclusions regarding the comparative results were not provided in that specific trial.

Pharmacokinetic Studies

Studies evaluated how the body absorbs, distributes, metabolizes, and excretes the compound.

  • Timing of Dose: Studies evaluated the absorption when the drug was taken at night, as part of chronopharmacokinetic research.
  • Specific Populations: Clinical trials included patients with mild liver impairment to evaluate the findings in this group regarding safety endpoints.

Key Studies & References A Randomized, Placebo-Controlled Phase III Trial of Compound A/B Combination for Acute Symptom Relief in Condition C

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Dolodran Extra Fuerte (FAQ)

Q: How long do the pain-relieving effects of Dolodran Extra Fuerte usually last?

The official dosing schedule requires that subsequent doses be separated by a minimum interval of 6 to 8 hours. This required interval establishes the minimum time that must pass between doses, which is an important safety measure defined in the official guidelines.

Q: What kind of pain is Dolodran Extra Fuerte most commonly used for?

According to official product indications, the medicine is used for the relief of pain, inflammation, and fever. The Diclofenac component is indicated for use in managing pain associated with inflammatory conditions, such as certain types of acute inflammation.

Q: Can Dolodran Extra Fuerte help with inflammation as well as pain?

Yes. Dolodran Extra Fuerte contains Diclofenac, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This component provides an essential anti-inflammatory action in addition to pain and fever relief.

Q: Why does the packaging say to take it with food?

Regulatory information specifies that the tablet should be taken with or immediately after food. This instruction is provided to help aid the tolerability of the medicine, which is a common practice with medications containing an NSAID component.

Q: Are there any long-term side effects associated with frequent use of Dolodran Extra Fuerte?

Official safety statements note that serious cardiovascular and gastrointestinal risks may potentially increase with the duration of use and at higher doses. Monitoring of liver and blood function is often recommended during prolonged exposure. Official guidelines emphasize that use should be limited to the shortest possible duration.

Q: Is it safe to take Dolodran Extra Fuerte if you are also taking blood pressure medication?

Regulatory warnings indicate that the Diclofenac component may cause a lessening of the antihypertensive effect of certain blood pressure medications, specifically ACE Inhibitors and ARBs. Official documentation notes this is a combination requiring special consideration and is detailed in the interactions section.

Q: Is Dolodran Extra Fuerte suitable for older adults?

Older adults are officially noted to have a greater risk of serious gastrointestinal and cardiovascular adverse events while using this medicine. Treatment for older adults involves careful consideration and may require initiating the medicine at the lowest effective dose, due to the increased risk profile.

Q: Is Dolodran Extra Fuerte generally safe for teenagers?

Official documentation states that children and adolescents below 14 years of age are generally not recommended for this strength. For patients aged 14 and over, use follows the official instructions and recommended dose limits, similar to those for adults.

Q: Do people use Dolodran Extra Fuerte for chronic pain or mainly acute issues?

According to official prescribing principles, the use of Dolodran Extra Fuerte is limited to the shortest possible duration necessary for symptom control. It is therefore not approved for chronic, continuous administration.

Q: Is it normal to feel a bit drowsy after taking Dolodran Extra Fuerte?

Official product information lists effects on the nervous system such as dizziness and headache. Additionally, drowsiness has been reported as a possible adverse effect.

Q: Is it possible to take Dolodran Extra Fuerte while pregnant or breastfeeding?

The medicine is formally contraindicated in the last trimester of pregnancy. Regarding breastfeeding, while only small amounts of the Diclofenac component may pass into breast milk, evaluation by a healthcare professional is necessary before considering use during this time.

Q: What should I do if I miss a dose of Dolodran Extra Fuerte?

Official consumer information provides specific guidance on how to manage a missed dose while adhering to safety rules. This guidance addresses when to take the dose and includes the prohibition against taking a double dose.

Q: What are the signs of a potential allergic reaction to Dolodran Extra Fuerte?

Regulatory documents list anaphylactic reactions and severe skin reactions as potential rare adverse effects. Patients with a known hypersensitivity to aspirin or other NSAIDs must not use this medicine.

Q: Is it safe to drive or operate machinery after taking this medicine?

The medicine may cause side effects such as dizziness or drowsiness. Because of these potential effects, caution should be exercised when engaging in tasks requiring full mental alertness, such as driving or operating machinery.

Q: What are the typical indications for Dolodran Extra Fuerte?

The medicine is officially indicated for the relief of pain, inflammation, and fever. It is generally used in conditions where a combination of both analgesic (pain-relieving) and anti-inflammatory action is considered beneficial.

Q: Why do some people experience ringing in the ears when taking certain pain relievers like this?

Ringing in the ears, known as tinnitus, has been reported as an occasional side effect of Diclofenac, the NSAID component of this combination medicine, according to regulatory-linked consumer information.

Q: Can Dolodran Extra Fuerte be used to reduce fever?

Yes. Dolodran Extra Fuerte is officially classified as an antipyretic (fever reducer) and is indicated for the relief of fever as part of its general therapeutic uses.

Q: Does the 'Fuerte' strength mean it has a higher risk of side effects?

Official safety statements note that serious risks, including cardiovascular events, may potentially increase with higher doses of the Diclofenac component. The Diclofenac component's risks are considered to be dose-dependent, meaning they increase with strength and dosage.

Q: What are the key instructions for using Dolodran Extra Fuerte safely?

Official guidelines emphasize that the medicine should be administered within precise parameters. These include taking the tablet whole with food, respecting the required time interval between doses, and limiting use to the shortest possible duration.

Q: Can I take Dolodran Extra Fuerte before a minor surgery?

The official documentation states use is contraindicated in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery. Since the medicine contains an NSAID which can affect blood clotting, use near any surgery requires assessment by a healthcare professional.

Q: What happens if you accidentally take more than the recommended dose?

Taking an excessive dose of this medicine carries a high risk of severe liver damage (hepatotoxicity) linked to the Acetaminophen component. Individuals should immediately seek emergency medical attention if an overdose is suspected.

Q: How is Dolodran Extra Fuerte eliminated from the body?

The active ingredients are primarily processed and metabolized in the liver. The metabolites of the Diclofenac component are then mainly excreted from the body through the urine and bile.

Q: Are there different formulations or delivery methods for Dolodran Extra Fuerte?

According to the official product information, Dolodran Extra Fuerte is supplied only as an oral tablet and is intended for systemic use. No other formulations or delivery methods for this specific combination product are detailed.

Q: Are there studies on the use of Dolodran Extra Fuerte in people with kidney issues?

Patients with severe renal failure are formally contraindicated from using the medicine. Official information provides specific guidelines for patients with mild to moderate kidney impairment, which often involves careful consideration of the dosage.

Q: Does the strength of Dolodran Extra Fuerte require any special precautions?

Yes. Due to its strength, special precautions are required, including adhering to the total daily dose limit and using the medicine for the shortest time needed for symptom control. This approach is required to help manage the dose-dependent safety risks associated with the active ingredients.

Advertisements

How should Dolodran Extra Fuerte be stored and disposed of?

Storage and Disposal Requirements

The official regulatory documents establish specific storage and handling mandates for Dolodran Extra Fuerte tablets (Acetaminophen and Diclofenac combination) to ensure product stability.

Labeled Storage Temperature: Store below 30 C or at controlled room temperature (20 to 25 C).
Environmental Protection: Must be protected from light and stored in a dry place.
Packaging Requirements: Keep the container tightly closed and store in the original container.
Child Safety Mandate: The medicine must be stored out of the reach and sight of children.
Disposal Instructions: Dispose of unused or expired product according to local regulations for pharmaceutical waste.

These mandated conditions define how the product must be stored and protected from temperature excursions, moisture, and light. Disposal must follow procedures set by local authorities for safe removal of medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dolodran Extra Fuerte found in:

A-Z Index: